盐酸缬更昔洛韦片使用说明

It has been on the market in China for some time. Its drug has excellent efficacy in treating patients with immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and in preventing CMV infection in high-risk solid organ transplant patients. It has been favored by many domestic and foreign patients. So how should patients use this drug?

adult patients

Induction therapy for CMV retinitis

For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of myelotoxicity.

Maintenance treatment of CMV retinitis

After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis. The duration of maintenance treatment should vary from person to person.

pediatric patients

The safety and effectiveness of valganciclovir hydrochloride tablets for the treatment of CMV retinitis in children have not been established through adequate and well-controlled clinical studies in pediatric patients.

Prevention of CMV infection in transplant patients

adult patients

For kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and until 200 days after transplantation.

For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days of transplantation and continuing until 100 days after transplantation.

Medication for pregnant and lactating women:

Due to the rapid and substantial conversion of valganciclovir to ganciclovir, reproductive toxicity studies have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects.

It is recommended that women of childbearing potential use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment.

There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus.

The developmental effects of valganciclovir or cyclovir on perinatal and postnatal infants have not been studied, but it must be considered that ganciclovir may be excreted in breast milk and cause serious adverse reactions in infants. Therefore, when considering the possible benefits of valganciclovir hydrochloride tablets to nursing mothers, a decision should be made to discontinue medication or discontinue breastfeeding.

Medication for children:

Safety and efficacy studies have not been conducted in children. Because the pharmacokinetics of valganciclovir hydrochloride tablets have not been studied in children, its use in children is not recommended.

Medication for elderly patients:

Safety and efficacy studies have not been conducted in older adults.